Leaderboards/HER2

HER2

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Aditya Bardia
Harbin Medical University
890 cit.
2
Nadia Harbeck
Breast Center
519 cit.
3
Kim A. Reiss
University of Pennsylvania
516 cit.
4
Javier Cortés
Hospital San Juan de la Cruz
360 cit.
5
Jinzhuo Wang
Center for Life Sciences
336 cit.
6
Fátima Cardoso
Champalimaud Foundation
309 cit.
7
Sheryl M. Gough
Arvinas (United States)
304 cit.
8
Giuseppe Curigliano
University of Milan
294 cit.
9
Sherene Loi
The University of Melbourne
273 cit.
10
Lin Shen
Peking University
231 cit.

Rising Stars Papers

1
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nature Medicine|2024
172 cit.
2
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Nature Medicine|2025
171 cit.
3
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Journal of Clinical Oncology|2024
124 cit.
4
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nature Medicine|2024
119 cit.
5
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
New England Journal of Medicine|2024
356 cit.
6
Self-improving generative foundation model for synthetic medical image generation and clinical applications
Nature Medicine|2024
111 cit.
7
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
Nature Medicine|2025
102 cit.
8
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Clinical Cancer Research|2024
151 cit.
9
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
Journal of Clinical Oncology|2024
97 cit.
10
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Nature Medicine|2025
90 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Jung‐Yun Lee
Yonsei University
963 cit.
2
Rui‐Hua Xu
Sun Yat-sen University
648 cit.
3
Sara M. Tolaney
Dana-Farber Cancer Institute
560 cit.
4
Sun Young Rha
Yonsei University
446 cit.
5
Sylvia K. Plevritis
Stanford University
390 cit.
6
Pasi A. Jänne
Dana-Farber Cancer Institute
353 cit.
7
Fabrice André
Inserm
351 cit.
8
Gabriel N. Hortobágyi
The University of Texas MD Anderson Cancer Center
308 cit.
9
Richard S. Finn
University of California, Los Angeles
255 cit.
10
Funda Meric‐Bernstam
The University of Texas MD Anderson Cancer Center
222 cit.

Emerging Leaders Papers

1
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology|2023
879 cit.
2
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Nature Medicine|2023
524 cit.
3
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
The Lancet|2023
446 cit.
4
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
The Lancet|2023
401 cit.
5
Analysis of Breast Cancer Mortality in the US—1975 to 2019
JAMA|2024
260 cit.
6
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Nature Medicine|2023
351 cit.
7
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Journal of Clinical Oncology|2023
279 cit.
8
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Journal of Clinical Oncology|2024
170 cit.
9
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Journal of Clinical Oncology|2024
148 cit.
10
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Cancer Discovery|2024
134 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Daniel F. Hayes
College of American Pathologists
27.5k cit.
2
Yoon‐Koo Kang
Asan Medical Center
21.8k cit.
3
Philip S. Bernard
University of North Carolina at Chapel Hill
14.6k cit.
4
Charles M. Perou
Segeberger Kliniken
11.7k cit.
5
Larry Norton
Memorial Sloan Kettering Cancer Center
11.5k cit.
6
Robert C. Millikan
University of North Carolina at Chapel Hill
11.5k cit.
7
Dennis J. Slamon
University of California, Los Angeles
11.3k cit.
8
Sibylle Loibl
Universitäts Frauenklinik
10.1k cit.
9
Solange Peters
University Hospital of Lausanne
9.8k cit.
10
Martin Schüler
Unknown
9.6k cit.

All-Time Leaders Papers

1
Comprehensive molecular portraits of human breast tumours
Nature|2012
12.3k cit.
2
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet|2010
7.3k cit.
3
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Journal of Clinical Oncology|2009
4.9k cit.
4
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Journal of Clinical Oncology|2006
4.5k cit.
5
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Journal of Clinical Oncology|2013
4k cit.
6
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine|2001
11.5k cit.
7
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
JAMA|2006
3.8k cit.
8
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology|2013
3.2k cit.
9
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology|2002
2.9k cit.
10
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
The Lancet|2021
2.9k cit.

All-Time Leaders Reagents

Coming soon

Indexing HER2 Reagents

Citation data for reagents in this field is currently compiling.